| Blood pressure lowering only or more? Has the jury reached its verdict? | |
| | |
MedLine Citation:
|
PMID: 17666196 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is a great need for antihypertensive agents that go beyond blood pressure lowering to treat the underlying pathophysiologic conditions that contribute to cardiovascular disease. However, the results of published outcome studies have been variable because they have investigated patients with complicated, high-risk hypertension. Although this ensures a sufficient number of cardiovascular events to demonstrate drug-drug differences, the potent effects of blood pressure lowering in high-risk patients obscures differential non-blood pressure effects. Despite these limitations, reductions in the risk of stroke, atrial fibrillation, and diabetes mellitus have been demonstrated with renin-angiotensin-aldosterone system blockade. Guidelines currently recommend thiazide diuretics in stage 1 hypertension, but this is based on data from high-risk patients, and extrapolation to stage 1 disease may not be appropriate. Both blood pressure and cardiovascular risk increase exponentially from early in a patient's life, leading to clinically relevant differences in the pathophysiology of stage 1 versus complicated hypertension. Importantly, patients with stage 1 hypertension typically require 30-40 years of treatment. Thus, secondary effects of antihypertensive drugs on various blood pressure-independent cardiovascular risk factors are likely to become manifest. Clinical trials in mild forms of hypertension are essential to investigate the non-blood pressure effects of antihypertensive agents. |
| | |
Authors:
|
Stevo Julius |
Related Documents
:
|
8080316 - Case study of the anemic patient: epoetin alfa--focus on blood pressure. 15529056 - New high blood pressure guidelines create new at-risk classification: changes in blood ... 14671496 - Does it matter how we lower blood pressure? 16211196 - Screening for hypertension in high school. 10694896 - Human retinal hemodynamics following administration of 5-isosorbide mononitrate. 1087586 - Intra-ocular pressure in onchocerciasis. some preliminary results of a field evaluation. |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-05-29 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 100 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-01 Completed Date: 2007-09-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 32J-37J Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. sjulius@med.umich.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
administration & dosage,
therapeutic use* Antihypertensive Agents / administration & dosage, therapeutic use* Cardiovascular Diseases / physiopathology, prevention & control* Drug Therapy, Combination Humans Hypertension / drug therapy*, physiopathology Renin-Angiotensin System / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blood pressure reduction and cardiovascular outcomes: past, present, and future.
Next Document: Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now...